Cardiovascular Safety of Febuxostat versus Allopurinol in Complex Patient Populations
Abstract
The cardiovascular safety of xanthine oxidase inhibitors in complex patient populations has emerged as a critical clinical consideration following conflicting evidence from major trials. This review synthesizes current evidence on the cardiovascular safety of febuxostat versus allopurinol in patient populations characterized by comorbidities, including chronic kidney disease, diabetes mellitus, and Asian ethnicity. There are raised concerns about the increased cardiovascular and all-cause mortal
Fields of Study & Subjects
Gout
Hyperuricemia
Uric Acid
Thyroid Disorders and Treatments
Inflammasome and immune disorders
Publication details
- Journal / source
- Journal Of Biochemical Technology
- Publisher
- Polaris
- Volume
- 17
- Issue
- 1
- Pages
- 108–113
- Publication date
- 1 January 2026